Multiple Sclerosis (MS) is a leading cause of unpredictable lifelong neurological disability in young adults, with a yet unexplained rise in incidence. The mechanisms underlying disease susceptibility and progression are still elusive and specific clinical translations are lacking. As such, the development of clinical molecular biomarkers represents a critical unmet need for MS management: early diagnosis and treatment decision are still challenging, disease trajectories are ascertained retrospectively, and prognosis remains unpredictable. MicroRNAs are small non-coding RNA molecules that have an important role in the fine tuning of all biological processes and are often found to be dysregulated in diseases, such as multiple sclerosis (MS). MS is an immune-mediated disease of the central nervous system characterized by demyelination, axonal loss and neurodegeneration.The aim of this study is to further understand the physiopathological function of miR-150 using experimental autoimmune encephalomyelitis (EAE), a mouse model for MS. To establish its role in-vivo, we generated miR-150 knock-out (KO) and knock-in (KI) mice using CRISPR/Cas9.RNAsequencing was performed on naive CD4T cells extracted from lymph nodes of the KI, KO and WT mice. cells were also polarised to Th1 , Th17 and Treg cells. The analysis of this data will allows to understand the role of miRNAs such as MiR150 in autoimmune neuroinflmmation.